CHICAGO, – Alfacell Corp.(ACEL) said on Tuesday it won U.S. orphan-drug designation for its lead cancer drug candidate Onconase, to treat a rare form of cancer caused by asbestos exposure.

Alfacell shares rose 22 cents to $1.85, or 13.5 percent.

Onconase is intended to treat malignant mesothelioma, a rare disease in which cancer cells form in the lining of the chest, abdomen or other organs.

But the drug is also being studied for non-small cell lung cancer, whose sufferers are an undertreated and much bigger patient market.

Orphan drug designation gives Alfacell seven years of marketing exclusivity, if it wins approval from the U.S. Food and Drug Administration.

Mesothelioma is primarily caused by exposure to asbestos. There are about 2,000 to 3,000 new cases each year in the United States, according to the American Cancer Society. The average survival time is one to two years.

Drug maker Eli Lilly (LLY) sells a drug for mesothelioma, Alimta, which is also used to treat non-small cell lung cancer.

Alfacel will perform a similar strategy, according to Ray Myers, director of research at brokerage EG Equities.

“It’s very common in oncology to get an orphan indication such as this for your first approval, because once you get approval its relatively easy to extend your label for bigger sales like for lung cancer,” said Myers, who has a “strong buy” rating on the stock.

In addition, doctors can prescribe an approved drug for any indication, known as “off-label use.”



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Ban Asbestos Now Act of 2017 proposed in Senate

At the end of October, the Environmental Protection Agency (EPA) announced it would be adjusting the...

EPA limits reach of toxic chemical evaluations

The EPA is reneging on promises to evaluate some of the most dangerous chemicals used by the public,...

Prevention remains the only way to end mesothelioma...

Mesothelioma is a deadly cancer that can affect the lining of the heart, the lining of the abdomen or,...

Controversial FACT Act headed to House floor for vote

The Furthering Asbestos Claim Transparency Act of 2017 (FACT Act) or H.R. 906, uses the guise of...
asbestos dust hazard perimeter tape

Canada joins countries implementing asbestos bans

Asbestos, a group of fibrous silicate minerals, is a known carcinogen and is closely linked to the...

Asbestos in schools poses mesothelioma risk. Who is...

According to the Environmental Protection Agency (EPA), approximately 15 million students and 1.4...

Best for clients

Great firm. Supports the community. They want what is best for their clients.

—Jennifer